Advantages of PleotherapyTM:

• Universal (can be applied to any disease)
• Patient-focused
• Particularly well suited to multifactorial diseases
• Integrates therapy and diagnosis early in the R&D process
• Allows patent protection
• Can shorten the R&D process to a total of around 11 years (compared with around ~16 years in the conventional process). Most of this time saving comes from preclinical phase because known, approved drugs are used. The first-in man trial would occur generally 2-3 years after initiation of the R&D program instead of the usual ~6-8 years (see the ongoing CMT1A program).
• Allows a high R&D sucess rate because of: (i) a better safety profile and less development failures, (ii) better potential efficacy as is already known for combination therapy and, (iii) the generation of several independent back-up candidates by the same research effort. 
• Dramatically reduces cost of pharmaceutical R&D as a consequence of the above beatures.
• A lower risk of rare, dramatic adverse events because of the use of low doses of drugs that have already been approved for long-term administration.  

It has already been shown that combination therapies (for cancer, infectious diseases, high blood pressure and inflammatory diseases) improve treatment efficacy while diminishing the risk of toxicity.